IL6, IL6R Found to Have Opposing Roles in Mortality

Genetic study reveals IL6 increases mortality, while IL6R reduces it through cardiovascular mechanisms

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

A new study published in Aging-US used large-scale Mendelian randomization to test whether genetically proxied levels of inflammatory biomarkers causally influence long-term all-cause mortality. The analysis found that genetically higher IL6R (soluble IL-6 receptor) levels were associated with reduced all-cause mortality and lower risk of cardiovascular diseases, while genetically higher IL6 levels were associated with increased mortality. The authors suggest these opposing effects point to distinct biological mechanisms, with IL6 promoting chronic inflammation and cardiovascular risk, while higher circulating IL6R appears to dampen harmful IL6 activity and provide cardiovascular protection.

Why it matters

This study provides important genetic evidence supporting IL6R antagonism as a potential strategy for cardiovascular disease prevention, as it suggests targeting the IL6R pathway could yield protective effects. The findings also highlight the complex interplay between inflammatory markers and mortality, with IL6 and IL6R having opposing causal roles.

The details

The study, led by Eliano P. Navarese, combined genome-wide association data from over 750,000 individuals and used FinnGen mortality data to assess the effects of inflammatory biomarkers on overall survival and major cardiovascular endpoints. Using robust Mendelian randomization methods, the authors report that genetically higher IL6R levels were associated with reduced all-cause mortality and lower risk of conditions like atrial fibrillation, coronary artery disease, stroke, and lung cancer. In contrast, genetically higher IL6 levels were linked to increased mortality. No significant causal effects were observed for CRP or GDF15.

  • The study was published on February 6, 2026 in the journal Aging-US.
  • The FinnGen mortality data used in the analysis had a median follow-up of 11.7 years.

The players

Eliano P. Navarese

The lead author of the study, from the Department of Life and Health Sciences at Link Campus University and the SIRIO MEDICINE Research Network at Nicolaus Copernicus University.

Aging-US

The journal that published the study.

Got photos? Submit your photos here. ›

What they’re saying

“These results support IL6R antagonism as a potential strategy for cardiovascular disease prevention.”

— Eliano P. Navarese, Lead author (Aging-US)

What’s next

The authors note that the analyses were restricted to individuals of European ancestry, so the results require replication in other ancestries. Translating the genetic evidence into preventive therapies will also need careful clinical evaluation, long-term safety assessment, and trials designed for primary prevention in high-risk populations. Additional mechanistic work is also called for to better understand how IL6/IL6R modulation alters vascular inflammation and downstream disease processes.

The takeaway

This genetic study highlights the complex and opposing roles of IL6 and IL6R in mortality, with IL6 increasing and IL6R reducing cardiovascular risk and overall mortality. The findings support further investigation of IL6R-targeted strategies for cardiovascular disease prevention, but also underscore the need for more research to fully elucidate the underlying biological mechanisms.